Maskwiomin (Birch Bark-Oil): Re-discovery of an L'nu skin ointment, working collaboratively with Indigenous communities through stories and awakening of knowledge, study of the processing of the oil and identification of active ingredients, and determinat

Maskwiomin(桦树皮油):重新发现 Lnu 皮肤软膏,通过故事和知识唤醒与原住民社区合作,研究油的加工和活性成分的识别,并确定

基本信息

  • 批准号:
    402605
  • 负责人:
  • 金额:
    $ 62.42万
  • 依托单位:
  • 依托单位国家:
    加拿大
  • 项目类别:
    Operating Grants
  • 财政年份:
    2019
  • 资助国家:
    加拿大
  • 起止时间:
    2019-03-01 至 2024-03-01
  • 项目状态:
    已结题

项目摘要

Birch bark-oil (maskwiomin) is an almost forgotten traditional L'nu medicine for the topical treatment of skin conditions such as rashes, eczema and psoriasis. Only two Elders of Membertou First Nation, Sydney, Nova Scotia held the knowledge of which one
桦树皮油(Maskwiomin)是一种几乎被遗忘的L传统药物,用于局部治疗皮疹、湿疹和牛皮癣。只有两位新斯科舍省悉尼门伯图第一民族的长老知道哪一个

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bierenstiel Matthias其他文献

Bierenstiel Matthias的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Development of Enhanced Anti-inflammatory Blood Mononuclear Cell Therapy for ARDS and Elucidation of the Molecular Mechanism
ARDS增强抗炎血液单核细胞治疗的进展及分子机制的阐明
  • 批准号:
    23K07659
  • 财政年份:
    2023
  • 资助金额:
    $ 62.42万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploring therapeutic effects of anti-inflammatory and resolving factors in osteoporosis model mice
探讨抗炎和缓解因子对骨质疏松模型小鼠的治疗作用
  • 批准号:
    23K15705
  • 财政年份:
    2023
  • 资助金额:
    $ 62.42万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigation of the relation between age-related estradiol fluctuation and pro-/anti-inflammatory effects in transplant immune response.
研究年龄相关雌二醇波动与移植免疫反应中促/抗炎作用之间的关系。
  • 批准号:
    23K19490
  • 财政年份:
    2023
  • 资助金额:
    $ 62.42万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
无涂层抗菌、抗宿主蛋白沉积、抗炎导尿管
  • 批准号:
    10697567
  • 财政年份:
    2023
  • 资助金额:
    $ 62.42万
  • 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
  • 批准号:
    10727765
  • 财政年份:
    2023
  • 资助金额:
    $ 62.42万
  • 项目类别:
Elucidation of anti-inflammatory mechanism of surface layer protein of lactic acid bacteria focusing on its interaction with lipopolysaccharide.
阐明乳酸菌表面层蛋白的抗炎机制,重点关注其与脂多糖的相互作用。
  • 批准号:
    23K13905
  • 财政年份:
    2023
  • 资助金额:
    $ 62.42万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
  • 批准号:
    23K08467
  • 财政年份:
    2023
  • 资助金额:
    $ 62.42万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
  • 批准号:
    493138
  • 财政年份:
    2023
  • 资助金额:
    $ 62.42万
  • 项目类别:
SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
SBIR I 期:蛋白酶激活受体 1 (PAR1) 抗炎调节剂的结构引导设计
  • 批准号:
    2223225
  • 财政年份:
    2023
  • 资助金额:
    $ 62.42万
  • 项目类别:
    Standard Grant
Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.
针对眼部 HSV-1 感染期间的抗病毒和抗炎反应,以预防视力障碍。
  • 批准号:
    10651054
  • 财政年份:
    2023
  • 资助金额:
    $ 62.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了